Friday, September 4, 2026

Pacific Biosciences of California And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Pacific Biosciences of California And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

2. Pacific Biosciences of California

73.4% sales growth and 15.06% return on equity

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems.

Pacific Biosciences of California's sales growth this year is expected to be 67% and 43.9% for next year.

Year-on-year quarterly revenue growth declined by 2.8%, now sitting on 78.89M for the twelve trailing months.

Pacific Biosciences of California's sales growth for the next quarter is 73.4%. The company's growth estimates for the ongoing quarter and the next is a negative 4600% and negative -20%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.06%.

Volatility

Pacific Biosciences of California's last day, last week, and last month's current volatility was 1.57%, 2.90%, and 4.02%, respectively.

Pacific Biosciences of California's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.39% (day), 7.65% (last week), and 7.98% (last month), respectively.

Pacific Biosciences of California's Stock Yearly Top and Bottom Value

Pacific Biosciences of California's stock is valued at $32.63 at 02:22 EST, way under its 52-week high of $53.69 and way higher than its 52-week low of $2.66.

Pacific Biosciences of California's Moving Average

Pacific Biosciences of California's worth is under its 50-day moving average of $33.94 and way above its 200-day moving average of $24.72.

3. Leidos Holdings, Inc.

15% sales growth and 17.26% return on equity

Leidos Holdings, Inc. provides services and solutions in the defense, intelligence, civil, and health markets in the United States and internationally.

Leidos Holdings, Inc.'s sales growth this year is anticipated to be 12.9% and 7.2% for next year.

Year-on-year quarterly revenue growth grew by 10.1%, now sitting on 12.3B for the twelve trailing months.

Leidos Holdings, Inc.'s sales growth for the next quarter is 15%. The company's growth estimates for the current quarter and the next is 24.4% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.26%.

Volatility

Leidos Holdings, Inc.'s last day, last week, and last month's current volatility was 0.63%, 0.24%, and 0.80%, respectively.

Leidos Holdings, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.52% (day), 1.37% (last week), and 1.80% (last month), respectively.

Leidos Holdings, Inc.'s Stock Yearly Top and Bottom Value

Leidos Holdings, Inc.'s stock is valued at $100.66 at 02:22 EST, way under its 52-week high of $113.75 and way higher than its 52-week low of $79.15.

Leidos Holdings, Inc.'s Moving Average

Leidos Holdings, Inc.'s worth is above its 50-day moving average of $97.15 and higher than its 200-day moving average of $98.72.

4. First Business Financial Services, Inc.

14.1% sales growth and 8.48% return on equity

First Business Financial Services, Inc. operates as the bank holding company for First Business Bank that provides commercial banking products and services for small and medium-sized businesses, business owners, executives, professionals, and high net worth individuals.

First Business Financial Services, Inc.'s sales growth this year is anticipated to be 6.1% and 1.2% for next year.

Year-on-year quarterly revenue growth grew by 2.4%, now sitting on 84.81M for the twelve trailing months.

First Business Financial Services, Inc.'s sales growth for the next quarter is 14.1%. The company's growth estimates for the current quarter and the next is 86.8% and 63.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.48%.

Volatility

First Business Financial Services, Inc.'s last day, last week, and last month's current volatility was 2.54%, 1.09%, and 1.11%, respectively.

First Business Financial Services, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.37% (day), 2.46% (last week), and 2.63% (last month), respectively.

First Business Financial Services, Inc.'s Stock Yearly Top and Bottom Value

First Business Financial Services, Inc.'s stock is valued at $24.65 at 02:22 EST, way below its 52-week high of $27.49 and way higher than its 52-week low of $13.43.

First Business Financial Services, Inc.'s Moving Average

First Business Financial Services, Inc.'s value is below its 50-day moving average of $25.37 and way above its 200-day moving average of $20.88.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com